Research programme: small molecule therapeutics - Nimbus Therapeutics

Drug Profile

Research programme: small molecule therapeutics - Nimbus Therapeutics

Alternative Names: NDI-031232; NDI-031301; NDI-031302

Latest Information Update: 24 Jan 2017

Price : $50

At a glance

  • Originator Nimbus Therapeutics
  • Class Small molecules
  • Mechanism of Action Interferon inhibitors; Interferon receptor agonists; KRAS protein inhibitors; TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation

Most Recent Events

  • 03 Dec 2016 Pharmacodynamic results from a preclinical study in Cancer reported at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
  • 10 Nov 2015 Preclinical trials in Cancer in USA (PO)
  • 10 Nov 2015 Preclinical trials in Inflammation in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top